280 related articles for article (PubMed ID: 34699525)
1. Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.
Ursprung S; Priest AN; Zaccagna F; Qian W; Machin A; Stewart GD; Warren AY; Eisen T; Welsh SJ; Gallagher FA; Barrett T
PLoS One; 2021; 16(10):e0258988. PubMed ID: 34699525
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
[TBL] [Abstract][Full Text] [Related]
3. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
Welsh SJ; Thompson N; Warren A; Priest AN; Barrett T; Ursprung S; Gallagher FA; Zaccagna F; Stewart GD; Fife KM; Matakidou A; Machin AJ; Qian W; Ingleson V; Mullin J; Riddick ACP; Armitage JN; Connolly S; Eisen TGQ
BJU Int; 2022 Aug; 130(2):244-253. PubMed ID: 34549873
[TBL] [Abstract][Full Text] [Related]
4. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
[TBL] [Abstract][Full Text] [Related]
5. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus.
Cai W; Huang J; Yuan Y; Hu X; Li M; Kong W; Zhang J; Guo J; Chen Y; Huang Y
Urol Int; 2018; 101(4):391-399. PubMed ID: 30184524
[TBL] [Abstract][Full Text] [Related]
7. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
[No Abstract] [Full Text] [Related]
8. Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience.
Abd Ghafar NK; Alip A; Ong TA; Yap NY; Saad M
J Cancer Res Ther; 2018; 14(6):1303-1311. PubMed ID: 30488848
[TBL] [Abstract][Full Text] [Related]
9. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
10. Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Wu G; Liu G; Kong W; Qu J; Suo S; Liu X; Xu J; Zhang J
Eur Radiol; 2017 Sep; 27(9):3574-3582. PubMed ID: 28130612
[TBL] [Abstract][Full Text] [Related]
11. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
[TBL] [Abstract][Full Text] [Related]
12. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma.
Qin SK; Jin J; Guo J; Wang JW; Zhou FJ; Huang YR; Ren XB; Ye DW; Pan S; Sajben P; Wang Q
Future Oncol; 2018 Aug; 14(18):1835-1845. PubMed ID: 29717651
[TBL] [Abstract][Full Text] [Related]
14. Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma.
Bharwani N; Miquel ME; Powles T; Dilks P; Shawyer A; Sahdev A; Wilson PD; Chowdhury S; Berney DM; Rockall AG
Br J Cancer; 2014 Feb; 110(3):616-24. PubMed ID: 24366299
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Nilsen GH; Beisland C; Straume O
Cancer Treat Res Commun; 2019; 19():100127. PubMed ID: 30913495
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
[TBL] [Abstract][Full Text] [Related]
17. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis.
Field CA; Cotta BH; Jimenez J; Lane BR; Yim K; Lee HJ; Ryan ST; Hamilton ZA; Patel S; Wang S; Kane CJ; Dey S; Mckay RR; Noyes S; Millard FE; Rini BI; Campbell SC; Derweesh IH
Clin Genitourin Cancer; 2019 Jun; 17(3):e505-e512. PubMed ID: 30808547
[TBL] [Abstract][Full Text] [Related]
19. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
[TBL] [Abstract][Full Text] [Related]
20. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]